Clinical Advances Will Expand Hematologic Cancer Market Opportunities

Published
14 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$16.33
88.8% undervalued intrinsic discount
15 Aug
US$1.83
Loading
1Y
-56.2%
7D
7.0%

Author's Valuation

US$16.3

88.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 27%

Shared on24 Apr 25
Fair value Decreased 16%

AnalystConsensusTarget has decreased revenue growth from 38.4% to 33.2%, increased profit margin from 12.3% to 16.8%, decreased future PE multiple from 68.5x to 51.2x and increased discount rate from 8.6% to 11.4%.

Shared on17 Apr 25
Fair value Decreased 6.39%

AnalystConsensusTarget has increased profit margin from 10.5% to 12.3%, decreased future PE multiple from 79.3x to 68.5x and decreased shares outstanding growth rate from 0.3% to 0.1%.